Posted: Wed Dec 02, 2009 8:39 pm Post subject: Novel Intranasal Nanoemulsion Vaccine Adjuvant
Novel Intranasal Nanoemulsion Vaccine Adjuvant Also Effective by Subcutaneous and Intramuscular Injection
NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company's novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections. The mice that received either SC or IM H5 antigen combined with nanoemulsion had maximal immune responses at least a 1000 fold higher than control animals that received the same antigen IM without the nanoemulsion adjuvant. SC and IM administered NanoBio adjuvanted vaccines should share many of the advantages, including antigen-sparing properties, previously demonstrated in studies where the adjuvant was administered intranasally.
It is encouraging that these strong immune responses were achieved without evidence of significant irritation or inflammation, which could differentiate these IM vaccines from currently approved IM adjuvants,...
Earlier this year, the U.S. Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. The Phase 1 study is ongoing.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum